Contrasting Glaukos (NYSE:GKOS) & Cannabix Technologies (OTCMKTS:BLOZF)

Glaukos (NYSE:GKOS) and Cannabix Technologies (OTCMKTS:BLOZF) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Glaukos and Cannabix Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1	1	12	0	2.79
Cannabix Technologies	0	0	0	0	0.00

Glaukos presently has a consensus price target of $178.08, indicating a potential downside of 1.69%. Given Glaukos’ stronger consensus rating and higher possible upside, research analysts plainly believe Glaukos is more favorable than Cannabix Technologies.

Volatility & Risk

Glaukos has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Cannabix Technologies has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Profitability

This table compares Glaukos and Cannabix Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
Cannabix Technologies	N/A	-300.86%	-258.30%

Earnings & Valuation

This table compares Glaukos and Cannabix Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$612.84 million	17.43	-$187.69 million	($3.25)	-55.74
Cannabix Technologies	N/A	N/A	-$3.36 million	($0.02)	-17.50

Cannabix Technologies has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Cannabix Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

99.0% of Glaukos shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Glaukos beats Cannabix Technologies on 8 of the 13 factors compared between the two stocks.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

About Cannabix Technologies

Cannabix Technologies Inc., a technology company, develops marijuana breathalyzer for employers, law enforcement, workplaces, and laboratories in the United States. It develops tetrahydrocannabinol breath analyzers, a point of care breath testing tool for the rapid detection of recent cannabis use; MS breath sampler; and contactless alcohol breathalyzer, as well as breath collection units. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.